EMA — authorised 20 April 2007
- Application: EMEA/H/C/000723
- Marketing authorisation holder: Pfizer Europe MA EEIG
- Local brand name: Toviaz
- Indication: Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.
- Status: approved